BAY-069

BAY-069 is a potent branched-chain amino acid transaminases 1 (BCAT1) and BCAT2 inhibitor with IC 50 values of 31 nM and 153 nM, respectively. BAY-069 also can be used as a chemical probe. BAY-069 can be used tor research anticancer In Vitro BAY-069 (compound 36a) (70 nM-50 μM; 72 h) inhibits cell proliferation of U-87 and MDA-MB-231. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: U-87 and MDA-MB-231 Concentration: 70 nM-50 μM Incubation Time: 72 h Result: Inhibited cell proliferation of U-87 and MDA-MB-231 with IC 50 s of 358 nM and 874 nM, respectively. In Vivo BAY-069 exhibits high metabolic stability after incubation with human liver microsomes (CL blood = 0.11 L/h/kg) and moderate metabolic stability after incubation with rat hepatocytes (CL blood = 1.8 L/h/kg); shows high permeability through Caco-2 cell monolayers with no hint of efflux . BAY-069 (0.3 mg/kg for i.v.; 0.6 mg/kg for p.o.; single dosage) exhibits a favorable pharmacokinetic profile after i.v. dosing with low blood clearance (CL blood ), moderate volume of distribution at steady state (V ss ), and intermediate terminal half-life (t 1/2 ). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats Dosage: 0.3 mg/kg for i.v.; 0.6 mg/kg for p.o. Administration: i.v. or p.o.; single dosage Result: Pharmacokinetic Parameters of BAY-069 in male Wistar rats . CL blood (L/h/kg) V ss (L/kg) t 1/2 (h), i.v. AUC norm (kg·h/L), i.v. AUC norm (kg·h/L), p.o. F (%), p.o. 0.64 0.25 1.6 2.9 2.5 89 Form:Solid IC50& Target:IC 50 : 31 nM (BCAT1), 153 nM (BCAT2)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet